Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC Capital Markets reiterated that the company’s upcoming TRAILBLAZER-3 trial ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts.

Wall Street analysts remain bullish on Eli Lilly, boasting an Average Brokerage Recommendation (ABR) of 1.46, largely between Strong Buy and Buy. However, brokerage recommendations often mislead more ...

Red Cat and Palladyne partner to advance autonomous multi-drone collaboration, transforming military operations and commercial use.

Pfizer has added another chapter to its long-running drug discovery collaboration with Chinese tech startup XtalPi, this time upgrading their molecular modeling work. The aim is to help “grasp ...

Seeking to develop novel medicines for cardiovascular disease, Novartis and ProFound Therapeutics have signed a four-year strategic collaboration. The agreement will allow the partners to combine ...

Novo Nordisk: End to Telehealth Collaboration, Mixed Amylin Data Weigh on Valuation We’re cutting our fair value estimate after lowering our near-term Wegovy sales estimates.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...